➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Medtronic
Mallinckrodt
AstraZeneca
Express Scripts
Dow
Johnson and Johnson

Last Updated: October 26, 2020

DrugPatentWatch Database Preview

Abatacept - Biologic Drug Details

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Recent Clinical Trials for abatacept

Identify potential brand extensions & biosimilar entrants

SponsorPhase
National Institute on Aging (NIA)Early Phase 1
University of UtahEarly Phase 1
Beth Israel Deaconess Medical CenterPhase 1/Phase 2

See all abatacept clinical trials

Recent Litigation for abatacept

Identify key patents and potential future biosimilar entrants

District Court Litigation
Case NameDate
Celgene Corporation v. Aurobindo Pharma Limited2018-07-06
CELGENE CORPORATION v. EMCURE PHARMACEUTICALS LTD.2018-06-28
AMGEN INC v. SANDOZ INC.2018-06-26

See all abatacept litigation

PTAB Litigation
PetitionerDate
Crescendo Bioscience, Inc2017-04-12

See all abatacept litigation

Pharmacology for abatacept
Ingredient-typeRecombinant Fusion Proteins
Physiological EffectDecreased Cytokine Activity

Patent Text Search: US Patents for abatacept

These patents were identified by searching patent claims

Supplementary Protection Certificates for abatacept

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2017000036530 Italy   Start Trial PRODUCT NAME: IBRUTINIB O SUO SALE FARMACEUTICAMENTE ACCETTABILE(IMBRUVICA); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/4/945, 20150707
01730049 Spain   Start Trial PRODUCT NAME: SARILUMAB; NATIONAL AUTHORISATION NUMBER: EU/1/17/1196; DATE OF AUTHORISATION: 20170623; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/17/1196; DATE OF FIRST AUTHORISATION IN EEA: 20170623
C1057 France   Start Trial PRODUCT NAME: SARILUMAB; REGISTRATION NO/DATE: EU/1/17/1196 20170627
2017038,C2041177 Lithuania   Start Trial PRODUCT NAME: SARILUMABAS; REGISTRATION NO/DATE: EU/1/17/1196 20170623
2008014 Lithuania   Start Trial PRODUCT NAME: ABATACEPTUM; REGISTRATION NO/DATE: EU/1/07/389/001, 2007 05 21, EU/1/07/389/002, 2007 05 21, EU/1/07/389/003 20070521
2016000093 Germany   Start Trial PRODUCT NAME: LBRUTINIB ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON; REGISTRATION NO/DATE: EU/1/14/945 20160526
1 Finland   Start Trial
>Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Mallinckrodt
Johnson and Johnson
Dow
Baxter
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.